摘要
伊立替康(CPT-11)是一种临床应用广泛的抗肿瘤药物,但其可能发生的严重不良反应却常常影响它的临床使用。有关报道称,特异性分布于肝细胞基底膜外侧的有机阴离子转运蛋白1B1(OATP1B1)可显著影响CPT-11及其活性产物SN-38的血药浓度,进而影响它的不良反应。文章就负责编码OATP1B1的编码基因SLCO1B1的基因多态性与CPT-11所致不良反应的关系作一综述。
Irinotecan （CPT-11） is used widely for the treatment of patients with cancers. Howev- er,its possible serious toxicities often hinder its clinical use. Some studies have shown that or- ganic anion transport protein 1B1 （OATP1B1） distributed specifically in lateral region of basement membrane can significantly affect the serum drug concentration of CPT-11 and its ac- tive product SN-38 ,and also affect its toxicities .This paper reviews the relationship between the toxieities caused by CPT-11 and gene polymorphism of SLCOIB1 which takes charge of codinz OATP1B1.
出处
《肿瘤学杂志》
CAS
2015年第5期432-435,共4页
Journal of Chinese Oncology
